BACKGROUND AND AIMS: Transsphenoidal surgery remains the treatment of choice in @entity2012 , yet 40-50% of @entity1 require secondary forms of therapy such as @entity1161 ( @entity1161 ) and @entity1943 analogues (SA). We undertook this study to evaluate the efficacy and safety of @entity1161 in @entity2012 . METHODS: Forty @entity1 with @entity2012 treated with @entity1161 (mean dose, 52 Gy) after failed pituitary surgery between 1993 and 2007 were analyzed; all were clinically and biochemically active. @entity1 were evaluated with yearly hormonal measurements [basal and @entity413 -suppressed @entity2124 ( @entity2124 ), @entity442 , thyroid-stimulating hormone (TSH), free T4, @entity701 , luteinizing hormone (LH), follicle-stimulating hormone (FSH), @entity251 or @entity53 and prolactin (PRL)] and with magnetic resonance imaging every 2 years. RESULTS: Mean age of @entity1 was 52.9    12.1 years and 85% were female. All subjects had been followed for 1 year, 75% for 3 years, 70% for 5 years and 35% for 10 years. The median basal @entity2124 level fell from a baseline of 8.8 ng/mL to 2.27 ng/mL at 5 years (p = 0.001) and to 1.88 ng/mL at 10 years (p = 0.001). A @entity2124 <1 ng/mL was achieved by 46% and 57% of the @entity1 at 5 and 10 years of follow-up, respectively. The proportion of @entity1 achieving a normal @entity442 was 36% at 5 years and 43% at 10 years. Before @entity1161 , @entity1375 , hypocortisolism and @entity6126 were present in 44%, 26% and 74% of @entity1 , respectively. After 5 years of follow-up (n = 28), these figures increased to 51%, 41% and 79% and over a third of the group had @entity7961 . One @entity1 developed @entity7995 and another @entity1 was diagnosed with a @entity1653 10 years after @entity1161 . No cerebrovascular events or @entity204 occurred. CONCLUSIONS: @entity1161 is an effective, low-cost and reasonably safe means of controlling acromegalic activity, particularly useful in parts of the world where SA are not readily available.

Efficacy and safety of radiotherapy in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1375 :: ('MESH:D007037', 'Disease') :: ['hypothyroidism'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT'] @entity442 :: ('3479', 'Gene') :: ['IGF-1'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol'] @entity2124 :: ('2688', 'Gene') :: ['GH', 'growth hormone'] @entity2012 :: ('MESH:D000172', 'Disease') :: ['acromegaly'] @entity7995 :: ('MESH:D009902', 'Disease') :: ['optic neuritis'] @entity1653 :: ('MESH:D008579', 'Disease') :: ['meningioma'] @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol'] @entity6126 :: ('MESH:D007006', 'Disease') :: ['hypogonadism'] @entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin'] @entity7961 :: ('MESH:C580003', 'Disease') :: ['panhypopituitarism'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity2012 :: (MESH:D000172,Disease) :: ['acromegaly']
